Wednesday, May 24, 2017 4:21:51 PM
The drug, emricasan, was tested in combination with another drug also in testing, birinapant. The study, performed in mice and human cancer cell cultures, demonstrated that the combo was more effective at killing the leukemic cells than birinapant alone.
A paper on the study was published Wednesday in the journal Science Translational Medicine. Paul G. Ekert and John Silke were the paper's senior authors and the first author was Gabriela Brumatti. All are of the University of Melbourne in Victoria, Australia. It can be found at http://j.mp/emribiri.
http://www.sandiegouniontribune.com/business/biotech/sdut-emricasan-liver-cancer-2016may19-story.html
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM